Tumor-Infiltrating Clonal Hematopoiesis
New England Journal of Medicine · 24.04.2025 · 392 (16) · 1594-1608
DOI: 10.1056/nejmoa2413361 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 24.04.2025. Verfasst von Oriol Pich und 47 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Clonal Hematopoiesis, Dioxygenases, DNA-Binding Proteins. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust, Cancer Research UK, NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition associated with increased mortality among patients with cancer. CHIP mutations with high variant-allele frequencies can be detected in tumors, a phenomenon we term tumor-infiltrating clonal hematopoiesis (TI-CH). The frequency of TI-CH and its effect on tumor evolution are unclear. METHODS: We characterized CHIP and TI-CH in 421 patients with early-stage non-small-cell lung cancer (NSCLC) from the TRACERx study and in 49,351 patients from the MSK-IMPACT pan-cancer cohort. We studied the association of TI-CH with survival and disease recurrence and evaluated the functional effect of TET2-mutant CHIP on the biologic features of lung tumors. RESULTS: Among patients with NSCLC, 42% of those with CHIP had TI-CH. TI-CH independently predicted an increased risk of death or recurrence, with an adjusted hazard ratio of 1.80 (95% confidence interval [CI], 1.23 to 2.63) as compared with the absence of CHIP and an adjusted hazard ratio of 1.62 (95% CI, 1.02 to 2.56) as compared with CHIP in the absence of TI-CH. Among patients with solid tumors, 26% of those with CHIP had TI-CH. TI-CH conferred a risk of death from any cause that was 1.17 times (95% CI, 1.06 to 1.29) as high as the risk with CHIP in the absence of TI-CH. TET2 mutations were the strongest genetic predictor of TI-CH; such mutations enhanced monocyte migration to lung tumor cells, fueled a myeloid-rich tumor microenvironment in mice, and resulted in the promotion of tumor organoid growth. CONCLUSIONS: TI-CH increased the risk of disease recurrence or death among patients with NSCLC and the risk of death from any cause among patients with solid tumors. TI-CH remodeled the tumor immune microenvironment and accelerated tumor organoid growth, findings that support a role for an aging-related hematologic clonal proliferation in cancer evolution. (Funded by the Royal Society and others.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London.
- Computational Clinical Oncology Laboratory, Unité Mixte de Recherche 981, Gustave Roussy, Villejuif, France.
- IHU PRISM (National Precision Medicine Center in Oncology), Gustave Roussy, Villejuif, France.
- Bone Marrow Dynamics Laboratory, Francis Crick Institute, London.
- Imperial College London, London.
- Haematopoietic Stem Cell Biology Laboratory, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
ORCID-Profile: Hector Huerga Encabo, Sally-Ann Clark, Supreet Kaur Bola, Julian Downward, Charles M Rudin, Dominique Bonnet
Förderung
- Wellcome Trust
- Cancer Research UK
- NCI NIH HHS
- European Hematology Association
- HORIZON EUROPE European Innovation Council
- European Research Council
- Horizon 2020 Framework Programme
- Medical Research Council
Zitieren
APA
Pich, O., Bernard, E., Zagorulya, M., Rowan, A., Pospori, C., Slama, R., Huerga Encabo, H., O'Sullivan, J., Papazoglou, D., Anastasiou, P., Iliakis, C. S., Clark, S. A., Dijkstra, K. K., Barbè, V., Bailey, C., Stonestrom, A. J., Enfield, K. S. S., Green, M., Brierley, C. K., …, & Swanton, C. (2025). Tumor-Infiltrating Clonal Hematopoiesis. New England Journal of Medicine, 392(16), 1594-1608. https://doi.org/10.1056/nejmoa2413361
Vancouver
Pich O, Bernard E, Zagorulya M, Rowan A, Pospori C, Slama R, et al. Tumor-Infiltrating Clonal Hematopoiesis. New England Journal of Medicine. 2025;392(16):1594-1608. doi:10.1056/nejmoa2413361
BibTeX
@article{Pich2025,
author = {Pich, Oriol and Bernard, Elsa and Zagorulya, Maria and Rowan, Andrew and Pospori, Constandina and Slama, Ramy and Huerga Encabo, Hector and O'Sullivan, Jennifer and Papazoglou, Despoina and Anastasiou, Panayiotis and Iliakis, Chrysante S and Clark, Sally-Ann and Dijkstra, Krijn K and Barbè, Vittorio and Bailey, Chris and Stonestrom, Aaron J and Enfield, Katey S S and Green, Mary and Brierley, Charlotte K and Magness, Alastair and Pearce, David R and Hynds, Robert E and Zaidi, Rija and Rane, Jayant K and Álvarez-Prado, Ángel F and Thol, Kerstin and Scott, Rachel and Bola, Supreet Kaur and Hoxha, Elena and Harris, Steve K and Peggs, Karl S and Quezada, Sergio A and Hackshaw, Allan and Zaccaria, Simone and Joyce, Johanna A and Malanchi, Ilaria and Berger, Michael F and Jamal-Hanjani, Mariam and Wack, Andreas and Downward, Julian and Grey, William and Lo Celso, Cristina and Grönroos, Eva and Rudin, Charles M and Mead, Adam J and Bonnet, Dominique and Papaemmanuil, Elli and Swanton, Charles},
title = {Tumor-Infiltrating Clonal Hematopoiesis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {16},
pages = {1594--1608},
doi = {10.1056/nejmoa2413361}
}
EUVIMED